

Table 1.22  
U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2014<sup>a</sup>  
Using Different Tumor Inclusion Criteria<sup>b</sup>

Site	Sex	5-Year Limited Duration			39-year Limited Duration	
		1st Invasive Tumor Ever <sup>c</sup>	1st Per Site in Previous 39 Years <sup>d</sup>	1st Per Site in Previous 5 Years <sup>e</sup>	1st Invasive Tumor Ever <sup>c</sup>	1st Per Site in Previous 39 Years <sup>d</sup>
All Sites	Both Sexes	4,707,603	4,804,644	5,327,036	14,176,073	14,407,725
	Male	2,358,463	2,396,232	2,650,453	6,724,873	6,805,012
	Female	2,349,140	2,408,412	2,676,583	7,451,200	7,602,713
Oral Cavity & Pharynx	Both Sexes	115,978	135,161	140,597	304,660	338,216
	Male	81,880	94,793	97,971	204,620	225,419
	Female	34,098	40,368	42,626	100,040	112,797
Esophagus	Both Sexes	22,547	27,932	28,052	38,340	45,433
	Male	17,820	21,866	21,937	30,067	35,402
	Female	4,727	6,066	6,115	8,273	10,031
Stomach	Both Sexes	40,042	48,260	48,945	81,801	94,587
	Male	23,682	28,847	29,232	46,828	54,495
	Female	16,360	19,413	19,713	34,973	40,092
Colon & Rectum	Both Sexes	387,571	446,369	455,675	1,169,200	1,300,518
	Male	199,704	229,611	234,110	585,071	648,151
	Female	187,867	216,758	221,565	584,129	652,367
Liver & Intrahepatic Bile Duct	Both Sexes	40,871	47,284	47,447	58,508	66,223
	Male	30,107	34,345	34,461	41,859	46,823
	Female	10,764	12,939	12,986	16,649	19,400
Pancreas	Both Sexes	39,896	48,921	48,944	53,505	64,361
	Male	20,062	24,740	24,763	26,229	31,846
	Female	19,834	24,181	24,181	27,276	32,515
Larynx	Both Sexes	31,963	37,495	38,022	87,985	98,733
	Male	25,808	30,349	30,784	70,747	79,284
	Female	6,155	7,146	7,238	17,238	19,449
Lung & Bronchus	Both Sexes	238,175	309,108	320,324	417,234	520,195
	Male	107,162	141,514	145,870	183,435	230,476
	Female	131,013	167,594	174,454	233,799	289,719
Melanoma of the Skin	Both Sexes	299,475	343,659	362,526	1,045,262	1,134,384
	Male	162,271	191,131	203,296	521,277	574,367
	Female	137,204	152,528	159,230	523,985	560,017
Breast	Female	906,033	984,111	1,048,649	3,097,860	3,287,692
Cervix	Female	38,533	40,724	40,793	218,501	224,665
Corpus & Uterus, NOS	Female	195,484	219,407	219,611	631,801	691,628
Ovary <sup>f</sup>	Female	61,143	70,057	70,127	184,919	207,305

<sup>a</sup> U.S. 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER 9 registries and 1/1/2014 U.S. population estimates based on the average of 2013 and 2014 population estimates from the U.S. Bureau of the Census.

<sup>b</sup> Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

<sup>c</sup> (c) First invasive tumor ever

<sup>d</sup> (d) First invasive tumor for each cancer site diagnosed during the previous 39 years (1975-2013)

<sup>e</sup> (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2009-2013)

For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2009; Melanoma in 2010.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 39-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2014.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 39-year limited duration prevalence. The 2009 breast cancer is counted for the breast 5-year and 39-year limited duration prevalence.

In method (e) the 2009 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2010 melanoma is counted for 5-year limited duration prevalence for melanoma.

<sup>f</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Table 1.22 - continued  
 U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2014<sup>a</sup>  
 Using Different Tumor Inclusion Criteria<sup>b</sup>

Site	Sex	5-Year Limited Duration			39-year Limited Duration	
		1st Invasive Tumor Ever <sup>c</sup>	1st Per Site in Previous 39 Years <sup>d</sup>	1st Per Site in Previous 5 Years <sup>e</sup>	1st Invasive Tumor Ever <sup>c</sup>	1st Per Site in Previous 39 Years <sup>d</sup>
Prostate	Male	958,284	1,038,106	1,038,153	2,896,908	3,084,494
Testis	Male	43,188	44,173	44,790	233,387	236,737
Urinary Bladder	Both Sexes	204,650	258,837	264,918	584,564	686,874
	Male	156,415	198,781	203,732	437,376	514,987
	Female	48,235	60,056	61,186	147,188	171,887
Kidney & Renal Pelvis	Both Sexes	161,395	197,797	200,804	403,200	471,919
	Male	101,224	125,184	127,262	241,820	285,673
	Female	60,171	72,613	73,542	161,380	186,246
Brain & Nervous System	Both Sexes	46,934	50,188	50,674	144,554	149,412
	Male	25,809	27,507	27,751	76,849	79,285
	Female	21,125	22,681	22,923	67,705	70,127
Thyroid	Both Sexes	202,213	226,966	227,711	637,312	686,320
	Male	45,343	53,812	53,948	137,898	152,992
	Female	156,870	173,154	173,763	499,414	533,328
Hodgkin Lymphoma	Both Sexes	36,864	39,181	39,262	185,935	191,423
	Male	20,013	21,282	21,338	96,384	99,217
	Female	16,851	17,899	17,924	89,551	92,206
Non-Hodgkin Lymphoma	Both Sexes	209,107	247,513	252,349	581,742	653,653
	Male	112,529	134,140	136,678	307,368	346,181
	Female	96,578	113,373	115,671	274,374	307,472
Myeloma	Both Sexes	64,023	75,648	76,097	102,617	118,273
	Male	34,735	42,231	42,518	55,465	65,186
	Female	29,288	33,417	33,579	47,152	53,087
Leukemia	Both Sexes	128,087	151,081	151,699	343,991	381,774
	Male	74,309	88,049	88,376	195,093	217,430
	Female	53,778	63,032	63,323	148,898	164,344
Acute Lymphocytic Leukemia	Both Sexes	17,262	17,937	17,937	77,350	78,272
	Male	9,297	9,674	9,674	42,200	42,660
	Female	7,965	8,263	8,263	35,150	35,612
Childhood (Ages 0-19)	Both Sexes	66,888	67,020	67,615	348,190	348,772
	Male	34,669	34,757	35,067	178,759	179,034
	Female	32,219	32,263	32,548	169,431	169,738
Kaposi Sarcoma	Both Sexes	7,115	7,712	7,712	27,719	29,174
	Male	6,562	7,119	7,119	26,210	27,519
	Female	553	593	593	1,509	1,655
Mesothelioma	Both Sexes	3,155	4,083	4,083	4,860	5,905
	Male	2,157	2,873	2,873	2,855	3,628
	Female	998	1,210	1,210	2,005	2,277

<sup>a</sup> U.S. 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER 9 registries and 1/1/2014 U.S. population estimates based on the average of 2013 and 2014 population estimates from the U.S. Bureau of the Census.

<sup>b</sup> Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

<sup>c</sup> (c) First invasive tumor ever  
<sup>d</sup> (d) First invasive tumor for each cancer site diagnosed during the previous 39 years (1975-2013)  
<sup>e</sup> (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2009-2013)  
 For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2009; Melanoma in 2010.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 39-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2014. In method (d) the 1981 melanoma is counted for the melanoma and all sites 39-year limited duration prevalence. The 2009 breast cancer is counted for the breast 5-year and 39-year limited duration prevalence. In method (e) the 2009 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2010 melanoma is counted for 5-year limited duration prevalence for melanoma.

Table 1.23  
U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2014<sup>a</sup>  
By Age at Prevalence

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.  
Please see the Prevalence Comparison Chapter of this CSR for more information.

Site/Sex	Age at Prevalence								
	All Ages <sup>c</sup>	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
All Sites									
Males	6,872,623	18,786	43,295	91,310	166,204	350,387	937,944	1,835,673	3,429,024
Females	7,866,096	17,222	37,437	93,801	242,346	639,430	1,424,917	1,995,951	3,414,992
Oral Cavity & Pharynx									
Males	230,233	45	454	1,771	3,759	13,831	51,146	76,136	83,090
Females	116,669	107	542	1,594	4,163	8,877	21,084	30,278	50,024
Esophagus									
Males	35,460	0	0	29	181	1,003	5,067	12,194	16,986
Females	10,087	0	0	0	44	190	1,441	2,846	5,566
Stomach									
Males	55,180	0	11	168	589	2,749	8,310	14,682	28,670
Females	40,584	0	44	210	842	2,454	5,947	9,160	21,926
Colon & Rectum									
Males	653,863	22	146	1,263	6,349	26,922	91,558	156,306	371,297
Females	663,384	0	261	1,482	6,650	24,542	80,676	130,589	419,183
Liver & Intrahep									
Males	46,895	611	536	603	632	1,608	11,275	19,864	11,766
Females	19,876	418	591	486	471	1,059	3,816	6,321	6,715
Pancreas									
Males	31,986	23	35	117	493	1,812	5,719	9,976	13,812
Females	32,682	0	23	347	628	1,721	5,972	8,601	15,389
Larynx									
Males	80,249	0	0	80	285	1,810	10,178	23,304	44,592
Females	19,665	0	0	17	142	859	3,485	5,914	9,247
Lung & Bronchus									
Males	234,540	34	98	470	1,266	5,330	26,088	64,649	136,605
Females	292,688	56	92	401	1,684	6,863	35,794	75,197	172,603
Melanoma of the Skin									
Males	585,672	67	706	4,931	18,016	45,764	104,327	160,068	251,795
Females	583,679	107	813	10,439	36,175	74,208	129,434	142,681	189,821

<sup>a</sup> U.S. 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2014 U.S. population estimates based on the average of 2013 and 2014 population estimates from the U.S. Bureau of the Census. Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39 years (1975-2013).

<sup>b</sup> Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

<sup>c</sup> Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

Table 1.23 - continued  
 U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2014<sup>a</sup>  
 By Age at Prevalence

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.  
 Please see the Prevalence Comparison Chapter of this CSR for more information.

Site/Sex	Age at Prevalence								
	All Ages <sup>c</sup>	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
Breast									
Males	18,835	0	0	11	76	672	2,123	5,001	10,951
Females	3,327,552	11	47	3,031	38,197	215,565	597,561	910,098	1,563,042
Cervix									
Females	256,078	0	81	2,075	14,495	40,908	60,284	61,931	76,305
Corpus & Uterus, NOS									
Females	710,228	11	35	727	6,574	27,036	100,667	205,938	369,240
Ovary <sup>d</sup>									
Females	222,060	81	1,038	3,954	7,233	18,751	46,165	61,136	83,701
Prostate									
Males	3,085,209	45	47	79	338	17,434	240,617	859,940	1,966,708
Urinary Bladder									
Males	521,201	68	117	524	2,521	9,466	44,105	118,578	345,823
Females	175,239	79	34	246	972	3,819	14,892	36,157	119,040
Kidney & Renal Pelvis									
Males	292,058	1,399	2,329	3,006	5,751	20,940	52,404	82,949	123,279
Females	191,167	1,616	2,455	3,238	5,310	13,603	33,033	47,535	84,377
Hodgkin Lymphoma									
Males	105,489	209	2,301	9,666	16,550	23,334	24,766	18,035	10,629
Females	98,576	45	2,147	9,466	16,634	22,567	23,051	14,306	10,361
Non-Hodgkin Lymphoma									
Males	350,647	831	4,019	8,336	14,494	30,378	61,177	88,332	143,081
Females	311,349	547	1,536	4,919	9,944	21,497	48,615	75,964	148,327
Myeloma									
Males	65,283	0	18	87	605	3,537	10,446	19,742	30,849
Females	53,256	0	0	69	480	2,374	8,379	15,856	26,099
Leukemia									
Males	219,989	6,599	13,513	14,405	12,981	16,403	29,092	46,712	80,285
Females	167,739	5,984	10,654	12,441	11,619	12,517	20,169	30,950	63,404
Acute Lymphocytic Leuk									
Males	44,485	5,568	11,217	11,145	7,420	5,011	2,295	1,096	732
Females	37,352	5,088	9,067	8,947	6,522	3,972	1,798	1,285	672

<sup>a</sup> U.S. 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2014 U.S. population estimates based on the average of 2013 and 2014 population estimates from the U.S. Bureau of the Census. Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39 years (1975-2013).

<sup>b</sup> Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

<sup>c</sup> Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.